Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Portfolio Pulse from Benzinga Insights
Iovance Biotherapeutics (NASDAQ: IOVA) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has decreased to $27.57 from $29.14. Analysts have maintained or lowered their ratings, reflecting varied sentiments about the company's future performance.
August 12, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Iovance Biotherapeutics has received mixed analyst ratings, with a majority being bullish. The average 12-month price target has decreased to $27.57 from $29.14, indicating a slight decline in analyst confidence.
The mixed analyst ratings and the slight decrease in the average 12-month price target suggest a neutral short-term impact on Iovance Biotherapeutics' stock price. While the majority of analysts remain bullish, the lowered price target indicates some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100